Last reviewed · How we verify
D565
At a glance
| Generic name | D565 |
|---|---|
| Sponsor | Chong Kun Dang Pharmaceutical |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate Drug-drug Interaction, Safety and Tolerability in Case of the Co-administration of D565 and D930 (PHASE1)
- The Pharmacokinetics of D565 and the Drug Effect of D565 on Pharmacokinetic Characteristics of D930 (PHASE1)
- Exploratory Trial to Evaluate the Efficacy and Safety of D565H Twice Daily Versus D565 Once Daily (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- D565 CI brief — competitive landscape report
- D565 updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI